Lipid-lowering drugs associated with slower motor decline in the elderly adults. by Dumurgier, Julien et al.
Lipid-lowering drugs associated with slower motor
decline in the elderly adults.
Julien Dumurgier, Archana Singh-Manoux, Be´atrice Tavernier, Christophe
Tzourio, Alexis Elbaz
To cite this version:
Julien Dumurgier, Archana Singh-Manoux, Be´atrice Tavernier, Christophe Tzourio, Alexis El-
baz. Lipid-lowering drugs associated with slower motor decline in the elderly adults.. Journals
of Gerontology, Series A, Oxford University Press (OUP): Policy B - Oxford Open Option D,
2014, 69 (2), pp.199-206. <10.1093/gerona/glt140>. <inserm-01150936>
HAL Id: inserm-01150936
http://www.hal.inserm.fr/inserm-01150936
Submitted on 12 May 2015
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
 1 
Lipid-lowering Drugs associated with Slower Motor Decline in the Elderly  
 
Julien Dumurgier,1, 2, 3 Archana Singh-Manoux,1, 3, 4, 5 Béatrice Tavernier,6 Christophe 
Tzourio,7, 8 and Alexis Elbaz1 ,3, 5 
 
 
1INSERM U1018, Centre for research in Epidemiology and Population Health, Social 
and occupational determinants of health, F-94807, Villejuif, France. 
2CMRR Paris Nord Ile-de-France, Lariboisiere Fernand Widal Saint Louis Hospital, 
Assistance Publique -Hôpitaux de Paris, University of Paris Diderot, Paris, France. 
3Univ Versailles St-Quentin, UMRS 1018, F-94807, Villejuif, France; 4Centre de 
Gérontologie, Hôpital Ste Périne, AP-HP, Paris, France. 
5Department of Epidemiology and Public Health, University College London, UK 
6CHU de Dijon, Department of Geriatrics, Dijon, France. 
7INSERM U708, Neuroepidemiology, Bordeaux, France. 
8Université Victor Segalen Bordeaux 2, Bordeaux, France. 
 
Adress correspondence to Julien Dumurgier, MD, PhD, Memory Center of 
Lariboisiere Hospital, 200 rue du Faubourg Saint-Denis, 75010, Paris, France.  
Email: julien.dumurgier@inserm.fr; Tel: +33 1 40 05 43 13, Fax: +33 1 40 05 43 39  
 
 
Running title: Lipid-lowering drugs and motor decline 
 
Abstract: 217 words 
Text, references, figure legends, and tables: 4960 words 
 
3 Tables, 1 Figure, 31 references 
Supplementary material online: supplementary methods, 6 supplementary tables, 1 
supplementary figure 
 
 2 
Background. Vascular risk factors contribute to motor decline in the elderly. We 
investigated the relationship between lipid-lowering drugs (LLDs) use and decline in 
walking speed (WS) in older adults. 
Methods. Data on 4009 community-dwelling men and women, aged ≥65y at baseline, 
are drawn from the Dijon (France) center of the Three-City study. “Fast” WS was 
assessed over 6 meters at baseline and at 4, 6, 8 and 10y of follow-up. Mixed linear 
models were used to determine the relationship between LLDs and change in WS over 
the follow-up.  
Results. At baseline, 1295 (32%) participants used LLDs (statins, n=643; fibrates, 
n=652); mean fast WS was 152.9 cm/s and not significantly different between LLDs 
users and non-users. In models adjusted for age, sex, cholesterol level, and other 
covariates, WS decline was 27% slower in LLDs users (difference with non-users: 0.58 
cm/s/year, 95% CI: 0.30, 0.86; P<0.001). Both fibrates and statins were associated 
with slower decline, but only the effect of statins was robust in analyses that took 
missing values into account. The beneficial effect was more pronounced in those on 
LLDs continuously over the follow-up.  
Conclusion. WS declined less in those on lipid lowering drugs, suggesting that the 
effect of LLDs, statins in particular, extend beyond that on cardiovascular disease in 
the elderly.  
 
Key Words: motor function — gait — lipid-lowering drugs — statins — ageing — 
epidemiology 
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Poor motor function in the elderly is associated with adverse health outcomes, 
including disability and death (1-3). Walking speed (WS), assessed over 3 to 6 metres 
in studies, is a reliable measure of overall motor function (4). Identifying risk factors 
associated with slower WS represents an important first step towards preventing poor 
motor function and disability at older ages. 
 Previous research has shown vascular risk factors (e.g., hypertension (5), 
diabetes mellitus(6)) to be associated with slower WS, there is emerging evidence that 
chronic inflammation may be associated with functional decline (7). Lipid metabolism 
abnormalities may also play a role: lower HDL-cholesterol has been associated with 
slower WS in the elderly (8), with cholesterol known to modify the association between 
chronic inflammation and motor performance (9). Besides lowering lipid levels lipid-
lowering drugs (LLDs), statins in particular have anti-inflammatory properties (10). For 
these reasons, statins could potentially have a protective effect on age-related 
functional decline (11). However, the results in this domain are inconsistent. Some 
studies, mostly cross-sectional, show LLD use to be associated with better motor 
performance (12-14), other studies report no association between use of LLDs and 
functional status in the elderly (15, 16). Cross-sectional studies are subject to biases 
such as reverse causation and residual confounding. Thus, it remains unknown 
whether use of LLDs is associated with motor decline. The objective of our study was 
to examine the association between use of LLDs and decline in motor function, using 
data from a large prospective cohort of community-dwelling elderly with up to four 
measures of WS over 10 years. We hypothesized that use of LLDs would be 
associated with slower decline of walking speed over the follow-up.  
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METHODS 
Study Population 
 The Three-City (3C) study is a cohort study of community-dwelling persons, 
aged ≥65y at baseline, from three French cities (Bordeaux, Dijon, Montpellier) (17). 
We used data from Dijon (N=4931), where a motor function substudy was conducted. 
After the baseline assessment, participants were seen approximately every two years; 
in total, six waves of data have been collected so far. Initially, only participants ≤85y 
were invited to follow-up screenings that included a measure of WS. From wave 2 
onwards, all participants, irrespective of age, were offered the opportunity of being 
seen at home. Participants with conditions that cause gait impairment (Parkinson’s 
disease, dementia, stroke, hip fracture) were excluded from the present analyses. The 
study protocol was approved by the Ethics Committee of Kremlin-Bicêtre University 
Hospital, and all participants signed an informed consent form. 
 
Walking Speed Assessment 
 WS was measured at the study center in participants ≤85y at baseline (wave 0, 
1999-2000), and again after approximately four (wave 2, 2003-2004), eight (wave 4, 
2007-2008), and ten years (wave 5, 2009-2010). Two tests were carried out; 
participants were first asked to walk at their ‘usual’ speed and then at ‘maximum’ 
speed, i.e., as fast as they could without running. WS was measured using two 
photoelectric cells connected to a chronometer placed in a corridor six meters apart. 
Walking speed was computed as six meters divided by time taken to complete the test 
in seconds. Participants were asked to start walking three metres before the start line 
where the photoelectric cells were placed, so that measured WS did not include the 
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acceleration time, and had more than 5 meters after the finish line to decelerate. 
Participants could do one trial before testing began to ensure that they understood the 
instructions. 
We used fast rather than usual WS in the main analysis for various reasons. 
One, in test-retest analysis the intraclass correlation coefficient was 0.84 (SE=0.02) for 
usual and 0.92 (SE=0.02) for fast WS (5). Although reliability was excellent for both 
measures, fast WS appears to be less prone to measurement error than usual WS. 
Two, change in WS over the follow-up was more pronounced for fast (2.0 cm/s/y) than 
usual (0.5 cm/s/y) WS, as has previously been reported by others (18, 19). Three, the 
variability of the slope was greater for fast (2.31, SE=0.32) than usual (0.81, SE=0.19) 
WS, suggesting greater heterogeneity in decline in fast WS. Analyses were repeated 
using usual WS to allow comparability with other studies. 
 
Medications 
 Interviewers recorded medications used by participants during the preceding 
month using medical prescriptions and drug packages. Drugs were coded using the 
French translation of the WHO Anatomical Therapeutic Chemical classification. LLDs 
use was defined using statins (C10AAxx) and fibrates (C10ABxx). We also recorded 
use of aspirin, antihypertensive, psychotropic, and nonsteroidal anti-inflammatory 
drugs (NSAIDs). 
 
Covariates 
 Data were collected during face-to-face interviews with trained psychologists 
using standardized questionnaires. Covariates included in the analysis were are age, 
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sex, education, income, health behaviours, body mass index, cardiovascular disease 
and risk factors, cognitive status, depression, and disability; described in 
supplementary methods. 
 
Statistical Analysis 
 Baseline participants' characteristics are presented overall and by baseline 
LLDs use and tertiles of WS, and compared using age- and sex-adjusted logistic/linear 
regression models. 
 Linear mixed models to examine the association between LLD use at baseline 
(yes/no) and change in WS using four measures over a ten year follow-up. Mixed 
models allow all available data to be used in the analysis in order to estimate the 
intercept (cross-sectional effect) and the slope (longitudinal effect). The intercept and 
slope are estimated together, with the correlation between them taken into account in 
the model. The intercept and slope were treated as random effects, allowing them to 
vary between individuals. Time since baseline was included as a continuous linear 
term after verification that a quadratic term did not improve model fit. Model 1 included 
baseline LLDs and was adjusted for age and sex, the strongest determinants of WS in 
our study, and HDL- and LDL-cholesterol and triglycerides, which were strongly 
associated with LLDs. Model 2 was further adjusted for covariates associated with WS 
and LLDs: BMI, height, education, hypertension, diabetes mellitus, coronary artery 
disease, psychotropic drugs, aspirin, homocysteine. The final model (Model 3) was 
further adjusted for covariates associated with WS or LLDs: depressive symptoms, 
MMSE, physical activity, alcohol consumption, smoking, PAD, NSAIDs. All covariates 
were drawn from the baseline assessment and models included their main effects and 
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interactions with time. Regression coefficients associated with LLDs use (yes/no) 
correspond to the mean difference in baseline WS between LLDs users and non-
users; coefficients for LLDs×time correspond to the mean difference in annual WS 
change between the two groups; positive coefficients correspond to slower decline in 
WS.  
 To investigate whether estimates of change in WS were influenced by those not 
on LLDs but with an indication for treatment, we performed analyses restricted to non-
LLDs users to compare those with an indication to LLDs to those without. LLDs 
indications were based on published guidelines based on LDL-cholesterol and other 
vascular risk factors (20). To examine the specificity of the association with type of 
LLD, we repeated the analyses using the following categories: no LLDs (reference), 
fibrates users, and statins users. 
The effect of change in LLDs use over time was assessed in two ways. First, we 
defined a three-level variable based on trajectories of LLDs over the follow-up: no 
LLDs at any examination (never users), intermittent use (started/stopped using LLDs 
during follow-up), persistent use (LLDs at all examinations). This approach allows the 
role of duration of use to be examined. Second, LLDs were included as time-
dependent variables together with their interaction with time. For both analyses, we 
used time-dependent covariates in the models. 
 In sensitivity analyses, we used propensity scores to better adjust for 
confounders (see supplementary methods). WS data over follow-up were missing due 
to death, age>85y, conditions with marked gait impairment, home examination (where 
WS was not measured), and non-response. To investigate the influence of missing 
data, we used multiple imputation (supplementary methods). 
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 Two-tailed P-values ≤0.05 were considered statistically significant. Analyses 
were performed using SAS 9.2 (SAS Institute, Cary, North Carolina, USA). 
 
 
RESULTS 
 At baseline, 4421 participants (65-85y) were seen at the study centre; 136 were 
excluded due to medical conditions that cause gait impairment, 4009 had at least one 
WS measure over the follow-up and LLDs data (supplementary figure). Participants 
not included in the analysis were older, had higher BMI, and lower physical activity and 
MMSE scores compared to those included in the analyses; the two groups did not 
differ with respect to use of LLDs or hypercholesterolemia. Among the 4009 
participants included in the analysis, 959 (23.9%) had four WS measures, 753 (18.8%) 
three, 944 (23.6%) two, and 1353 (33.7%) one. Participants with one measure were 
older (75.6y vs 72.3y, P<0.001) and walked slower (143 cm/s vs 158 cm/s, P<0.001) 
than participants with more measures, but were not different for LLDs use (31.3% vs. 
32.8%, P=0.35); 61% of the participants with one WS measure became older than 85y 
over the follow-up, died, or developed incident conditions causing gait impairment 
during the follow-up. 
 Table 1 presents participants' characteristics at baseline (mean (SD) age, 73.4y 
(4.6); 62% women; mean (SD) fast WS: 153 (31) cm/s; 1295 (32%) LLDs users, 
fibrates, n=652, statins, n=643). After adjustment for age and sex, LLDs use was 
associated with higher BMI, lower height, lower education, hypertension, diabetes 
mellitus, coronary artery disease, and aspirin use. LLDs users had lower total, HDL-, 
LDL-cholesterol, and triglycerides, and higher homocysteine. Slower baseline WS was 
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associated with lower socioeconomic status and with an unfavourable health profile, 
including LLDs use and lower HDL-cholesterol, and higher triglycerides and 
homocysteine. Compared to fibrates users, particpants on statins were more often 
men and had a history of coronary heart disease and higher triglycerides levels 
(supplementary table 1). 
 Table 2 shows the association between baseline LLDs use (yes/no) and change 
in fast WS over the follow-up. The annual decline in WS was -2.18 cm/s (95% CI: -
2.37 to -2.00; P<0.001) in those not on LLDs at baseline and -1.64 cm/s (95% CI: -
1.88 to -1.41; P<0.001) in those on LLDs, a statistically significant difference of 0.54 
cm/s (95% CI: 0.27 to 0.80; P<0.001), corresponding to 27% slower decline in those 
on LLDs. This difference was robust to adjustment for covariates (Model 3, β=0.58, 
95% CI: 0.30 to 0.86; P<0.001). Baseline cholesterol and triglycerides levels or other 
medications (NSAIDs, psychotropic drugs, aspirin) were not associated with WS 
change.  
 Among 2714 participants not on LLDs at baseline, 609 (22%) had an indication 
for treatment. The annual decline in WS in this group did not differ from that in 
participants without such an indication (Model 3, difference in decline=-0.15, 95% CI: -
0.60 to 0.29; P=0.50). 
 Change in WS as a function of type of LLDs, fibrates or statins, is presented in 
figure 1 and supplementary table 2. Both fibrates (Model 3, β=0.48, 95% CI: 0.10 to 
0.86; P=0.009) and statins (β=0.67, 95% CI: 0.31 to 1.02; P<0.001) were associated 
with slower WS decline, the effect was more pronounced for statins but not 
significantly different from the effect of fibrates (P=0.31). 
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 Over the follow-up, 2354 (59%) participants reported never using LLDs, 574 
(14%) were intermittent and 1081 (27%) persistent users. Table 3 shows the 
relationship between these categories and change in WS. Persistent users had slower 
decline in WS (M3, β=0.96, 95% CI: 0.25 to 1.67; P=0.007) compared to never users, 
while intermittent users were not significantly different from non-users (Model 3, 
β=0.37, 95% CI: -0.36 to 1.10; P=0.32). 
 Analyses including time-dependent LLDs use instead of baseline LLDs use 
yielded similar results (supplementary table 3); in addition, the association between 
LLDs and change in WS was somewhat stronger in fully adjusted models. 
 In sensitivity analyses (propensity scores), 1116 (86%) baseline LLDs users 
were matched to 1116 untreated participants (supplementary table 4); no differences 
were observed for matching covariates between them. LLDs at baseline remained 
associated with slower WS decline (supplementary table 5); the estimate (Model 3, 
β=0.57, 95% CI: 0.08 to 1.06; P=0.02) was similar to that in the main analysis. 
 Multiple imputation was used to replace missing values and subsequent 
analyses yielded findings consistent with our main analyses (supplementary table 6). 
In multivariable models, decline in WS was less pronounced in LLDs users compared 
to non-users: this difference (0.31 cm/s/year, 95% CI: 0.06 to 0.56; P=0.01) was less 
pronounced than in the main analyses but was robust to multivariable adjustment 
(Models 2 & 3). The effect was stronger for statins (0.40 cm/s/year, 95% CI: 0.09 to 
0.71; P=0.01) than for use of fibrates (0.23 cm/s/year, 95% CI: -0.10 to 0.57; P=0.17) 
(Figure 1).  
 
DISCUSSION 
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 In this large cohort of community-dwelling elderly persons, use of LLDs was 
associated with 27% slower 10-year decline in WS. Although LLDs users had a higher 
prevalence of characteristics associated with poorer motor performance (e.g., higher 
BMI, hypertension, coronary artery disease), the results showing slower decline in 
walking speed were robust to adjustment for these factors. In addition, this association 
was stronger among persistent LLDs users and those on statins rather than fibrates. 
Although both fibrates and statins were associated with slower WS decline in the main 
analyses, only statins had an effect that was robust to consideration of missing values 
using multiple imputation. 
 Few studies, mostly cross-sectional in nature, have investigated the relationship 
between LLDs and motor function in the elderly. One study (N=641) reported that 
subjects with and without peripheral arterial disease (PAD) taking statins had better 
motor performance assessed using a 6-minute walk test (12). In another study (332 
PAD patients), the annual decline in lower-extremity performance was less 
pronounced in patients on statins, while no effect was observed in 212 participants 
without PAD (13). In the Connecticut Veterans Longitudinal Cohort (N=756), statin 
users performed better than non-users at timed chair stands (14). Another study 
showed no association between use of statins and self-reported mobility limitation 
(21), and a recent study reported no relationship between statin use and physical 
performance; statin use was not associated with baseline WS or decline in WS in this 
large cohort of older women (15). However, the proportion of participants treated by 
statins was lower (9.3%) in the study than in our study (16.0%), and the study used a 
measure of “usual” WS which is known to decline less over time than fast WS. Our 
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analysis using a measure of usual walking speed suggests similar associations, 
particularly among the statin users. 
 Various mechanisms may account for an association between LLDs and slower 
motor decline. First, fibrates (22) and statins (23) increase HDL-cholesterol, which has 
been linked to better performance on measures of physical function (8, 24). In our 
study, baseline HDL-cholesterol was not associated with baseline or WS change in 
aanalysis adjusted for covariates. However, we did not have data on HDL-cholesterol 
levels before WS was measured, and as it was not measured again over the follow-up, 
we were unable to assess the impact of change in HDL-cholesterol on decline in motor 
function. Two, higher levels of inflammatory markers have been associated with poorer 
physical performance (25), and our results could be explained by the fact that statins 
reduce levels of inflammatory markers (10). Three, statins have a favourable effect on 
atherosclerosis and vascular function, independently of cholesterol levels (26). Four, 
cerebral white matter lesions (WML), i.e., small lesions supposedly of ischemic origin, 
are associated with poorer physical performance in the elderly (27), and higher 
cholesterol levels are associated with WMLs in some studies (28); however, whether 
LLDs use reduces the progression of WMLs remains controversial (29). Finally, statins 
may have neuroprotective properties (30), mediated by the activation of 
neuroprotective signaling pathways (31), or systemic effects such as reduction of 
oxidative damage (32) and improvement of vascular function (33). 
 In our study, the proportion of participants using fibrates and statins at baseline 
was very similar. This study’s baseline assessment took place in 1999-2000, fibrates 
were frequently used in France at that period. One observational European study 
reported that 54% of LLDs users in France in 1999 were on fibrates (34). The 
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subsequent decade was marked by a large increase in the use of statins, following the 
National Cholesterol Education Program Third Adult Treatment Panel (ATP-III) 
guidelines, published in 2001 (35). 
 The clinical relevance of our findings lie in the fact that LLDs are under-
prescribed in the elderly (Sheppard et al. BMJ 2012) with some concern that they may 
have harmful effects (refs). Our analysis using a longitudinal design in a large cohort of 
community dwelling elderly suugests that LLDs use was associated with a 27% slower 
decline in WS. Accelerated deline in WS is knon to be associated with adverse heatl 
outco;es such as mortality (Sabia et al. in press). It is possibl tha some of these effects 
are undersatimated as data come from a well-functioning community-dwelling elderly 
paticpants where the average decline in WS was not large.  
 This study has several strengths, including its large size, the long follow-up with 
up to four assessments of WS and use of LLDs, which allowed us to examine 
trajectories of LLDs use, and the assessment of a wide range of covariates. Its main 
limitation is its observational design. Adherence to LLDs therapy may be associated 
with use of health services, resulting in “healthy user bias” (36). On the other hand, the 
association between LLDs use and change in WS was robust to adjustment for a 
range of covariates, and was stronger in analyses using time-dependent meaures of 
use of LLDs. Therefore, although some level of unmeasured confounding cannot be 
ruled out, it seems implausible that it could account entirely for the association 
between LLD and decline in WSobsereved in our study. In addition, other medications 
(NSAIDs, psychotropic drugs, aspirin) were not associated with WS decline and its 
association with LLDs use was not attenuated after adjustment for other drugs. It is 
unlikely that our findings are confounded by socioeconomic status (SES), because 
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analyses were adjuste/d for education and access to medical care which in France is 
independent of SES as reimbursement for medication is at a high level for everyone. 
Furthermore, income was not associated with LLD use in our study. Propensity scores 
are a way to reduce bias in estimates of treatment effects in observational studies, and 
sensitivity analyses using this method replicated our main findings. Although 
observational studies have limitations, motor decline is a slow and progressive 
process making it unrealistic to envision that it would be possible to implement a 
clinical trial to examine the impact of LLD use on decline in motor function. Such a trial 
would face difficulties for an outcome such as WS decline, primarily due to the 
necessity to follow a large population of elderly people over a long period of time; this 
is similar to identifying protective factors for cognitive decline and dementia(37). 
Another limitation of our study is that WS was not measured over the follow-up in all 
participants; we used multiple imputation to deal with missing values using data on 
important surrogates (e.g., disability, falls) and found results that were similar to those 
of our main analysis. Finally, regarding the clinical relevance of our findings, the 
difference in change in WS between LLDs users and non-users corresponds to the 
effect of 8 years of ageing among untreated subjects in multivariable analyses, and is 
therefore not negligible. 
 In summary, LLDs were associated with slower decline in WS in a large 
population of community-dwelling elderly people followed up to 10 years. There is 
considerable evidence of under-prescription of LLDs in the elderly (38); in our study, 
only two-thirds of those with an adverse lipid profile were on LLDs. These findings 
extend previous research showing that in the elderly LLDs may have beneficial effects 
beyond cardiovascular disease by providing evidence that these drugs may slow 
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motor decline. 
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Figure 1. Predicted trajectories of fast walking speed according to baseline use of statins or 
fibrates. 
Solid line: no LLDs use ; short-dashed line: fibrates; long-dashed line: statins.  
Panel A: main analysis; Panel B: analysis based on multiple imputation of missing values 
(Supplementary Table 2, model 3). 
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Table 1. Baseline Characteristics of the Study Population 
    Baseline LLDs use*  Baseline fast walking speed (tertiles)† 
  Overall  No  Yes    T1‡ T2 T3   
Baseline characteristics    (N=4009)   (N=2714)  (N=1295) P-value§    (N=1255) (N=1258) (N=1195) P-value¶ 
Age, mean (SD)  73.4 (4.6)  73.4 (4.7) 73.2 (4.4) 0.20  75.3 (4.7) 73.2 (4.5) 71.7 (4.2) <0.001 
Women, n (%)  2472 (61.7)  1656 (61.0) 816 (63.0) 0.22  764 (60.9) 824 (65.5) 701 (58.7) <0.001 
Height, cm, mean (SD)  161.8 (8.8)  162.0 (8.9) 161.2 (8.4) 0.01  160.5 (8.8) 161.3 (8.7) 163.5 (8.5) <0.001 
BMI, kg/m2, mean (SD)  25.7 (4.0)  25.5 (4.0) 26.1 (3.9) <0.001  26.7 (4.4) 25.4 (3.8) 24.9 (3.5) <0.001 
Primary school or less, n (%)  2551 (63.7)  1694 (62.5) 857 (66.2) 0.04  921 (73.6) 804 (63.9) 641 (53.6) <0.001 
High income, n (%)**  1305 (35.0)  897 (35.4) 408 (34.1) 0.58  307 (26.6) 404 (34.7) 496 (43.5) <0.001 
Depressive symptoms, n (%)  507 (12.8)  332 (12.4) 175 (13.6) 0.27  224 (18.2) 143 (11.4) 113 (9.5) <0.001 
MMSE, mean (SD)  27.5 (1.9)  27.5 (1.9) 27.4 (1.9) 0.12  27.0 (2.1) 27.6 (1.8) 27.8 (1.7) <0.001 
Low physical activity, n (%)  748 (19.1)  524 (19.8) 224 (17.6) 0.08  371 (30.3) 258 (20.7) 230 (19.5) <0.001 
Current drinker, n (%)  3159 (79.0)  2130 (78.7) 1029 (79.6) 0.31  973 (77.7) 985 (78.4) 964 (80.9) 0.01 
Smoking ≥ 20 pack-years, n (%)  658 (16.7)  447 (16.7) 211 (16.6) 0.68  216 (17.4) 199 (16.0) 190 (16.2) 0.01 
Hypertension, n (%)  3167 (79.0)  2102 (77.5) 1065 (82.2) <0.001  1073 (85.5) 980 (77.9) 882 (73.8) <0.001 
Diabetes mellitus, n (%)  352 (9.1)  204 (7.7) 148 (11.8) <0.001  144 (11.8) 100 (8.2) 86 (7.4) <0.001 
Coronary artery disease, n (%)  406 (10.1)  194 (7.2) 212 (16.4) <0.001  173 (13.8) 115 (9.1) 88 (7.4) <0.001 
Peripheral artery disease, n (%)  126 (3.2)  83 (3.1) 43 (3.4) 0.48  59 (4.8) 29 (2.3) 30 (2.5) 0.003 
NSAIDs, n (%)  356 (8.9)  237 (8.7) 119 (9.2) 0.69  149 (11.9) 109 (8.7) 72 (6.0) <0.001 
Psychotropic drugs, n (%)  1004 (25.0)  652 (24.0) 352 (27.2) 0.03  419 (33.4) 302 (24.0) 223 (18.7) <0.001 
Aspirin, n (%)  561 (14.0)  297 (10.9) 264 (20.4) <0.001  220 (17.5) 154 (12.2) 139 (11.6 0.01 
LLDs, n (%)  1295 (32.3)  — — —  407 (32.4) 432 (34.3) 365 (30.5) 0.02 
Fibrates, n (%)  652 (16.3)  — — —  213 (17.0) 230 (18.3) 172 (14.4) 0.13 
Statins, n (%)  643 (16.0)  — — —  194 (15.5) 202 (16.1) 193 (16.2) 0.13 
Cholesterol, mmol/L, mean (SD)  5.81 (0.97)  5.96 (0.96) 5.51 (0.90) <0.001  5.83 (1.01) 5.76 (0.95) 5.83 (0.91) 0.43 
LDL-cholesterol, mmol/L, mean (SD) 3.62 (0.85)  3.75 (0.84) 3.34 (0.79) <0.001  3.64 (0.88) 3.56 (0.84) 3.64 (0.80) 0.52 
HDL-cholesterol, mmol/L, mean (SD) 1.64 (0.40)  1.65 (0.40) 1.63 (0.40) 0.031  1.60 (0.40) 1.66 (0.40) 1.66 (0.39) <0.001 
Triglycerides, mmol/L, mean (SD)†† 1.12 (0.46)  1.14 (0.45) 1.08 (0.47) <0.001  1.18 (0.48) 1.09 (0.44) 1.07 (0.43) <0.001 
Homocysteine, µmol/L, mean (SD) 14.9 (5.5)   14.1 (4.7) 16.6 (6.6) <0.001   15.8 (5.9) 14.6 (5.1) 14.3 (5.6) <0.001 
Walking speed, cm/s, mean (SD) † 152.9 (30.7)  153.7 (31.5) 151.4 (29.0) 0.02  123.3 (18.6) 152.2 (11.8) 184.9 (21.9) <0.001 
*
 4009 participants with at least one measure of fast walking speed during the follow-up. 
†
 3708 participants with a baseline fast walking speed measure. 
‡
 Sex-dependent tertiles; men: T1, ≤150 cm/s; T2, 151-180 cm/s; T3, >180 cm/s; women: T1, ≤133 cm/s; T2, 134-150 cm/s; T3, >150cm/s. 
§
 Age- and sex-adjusted logistic regression models. 
¶ Age- and sex-adjusted linear regression models with continuous walking speed as the dependent variable.  
**
 Income greater than 15000 French francs per month. 
††Geometric mean.
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Table 2. Association between LLDs use at baseline and change in ”fast” walking speed (cm/s) over the follow-up 
  Model 1  Model 2  Model 3 
Change in fast walking speed   Estimate (95% CI) P-value   Estimate (95% CI) P-value   Estimate (95% CI) P-value 
Time (y)  -2.18 (-2.37 to -2.00) <0.001  -2.27 (-2.68 to -1.87) <0.001  -2.40 (-2.87 to -1.92) <0.001 
Age x Time  -0.06 (-0.09 to -0.02) <0.001  -0.07 (-0.10 to -0.03) <0.001  -0.07 (-0.10 to -0.04) <0.001 
Sex (men vs women) x Time  -0.26 (-0.53 to 0.01) 0.06  0.26 (-0.11 to 0.63) 0.16  0.18 (-0.20 to 0.57) 0.35 
LLDs use x Time  0.54 (0.27 to 0.80) <0.001  0.54 (0.27 to 0.82) <0.001  0.58 (0.30 to 0.86) <0.001 
LDL-cholesterol x Time  0.12 (-0.04 to 0.27) 0.14  0.07 (-0.09 to 0.22) 0.40  0.04 (-0.12 to 0.20) 0.64 
HDL-cholesterol x Time  0.26 (-0.11 to 0.63) 0.17  0.10 (-0.28 to 0.47) 0.61  0.14 (-0.25 to 0.52) 0.49 
Triglycerides (log) x Time   -0.18 (-0.53 to 0.18) 0.31  -0.10 (-0.46 to 0.25) 0.57  -0.12 (-0.49 to 0.25) 0.53 
Model 1: Adjusted for age, sex, LLDs, baseline cholesterol and triglycerides, and their interactions with time.  
Model 2: Model 1 + baseline height, BMI, education, hypertension, diabetes mellitus, coronary artery disease, psychotropic drugs, aspirin, homocysteine, 
and their interactions with time. 
Model 3: Model 2 + baseline depressive symptoms, MMSE, physical activity, alcohol, smoking, peripheral artery disease, NSAIDs, and their interactions 
with time. 
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Table 3. Association between trajectories of LLDs use and change in “fast” walking speed (cm/s) over the Follow-Up 
  Model 1  Model 2  Model 3 
Change in fast walking speed   Estimate (95% CI) P-value   Estimate (95% CI) P-value   Estimate (95% CI) P-value 
Time (y)   -2.18 (-2.38 to -1.98) <0.001  -2.60 (-3.48 to -1.72) <0.001  -2.79 (-4.16 to -1.42) <0.001 
Age x Time  -0.06 (-0.09 to -0.03) <0.001  -0.07 (-0.14 to -0.01) 0.03  -0.04 (-0.12 to 0.04) 0.28 
Sex (men vs women) x Time  -0.30 (-0.57 to –0.03) 0.03  0.04 (-0.78 to 0.87) 0.92  0.26 (-0.63 to 1.16) 0.56 
LLDs use x Time          
None x Time  Reference ―  Reference ―  Reference ― 
Intermittent x Time  0.11 (-0.19 to 0.42) 0.47  0.26 (-0.45 to 0.97) 0.47  0.37 (-0.36 to 1.10) 0.32 
Persistent x Time  0.51 (0.21 to 0.81) <0.001  1.04 (0.35 to 1.72) <0.001  0.96 (0.25 to 1.67) 0.007 
LDL-cholesterol x Time  0.42 (-1.26 to 2.10) 0.63  -0.20 (-3.66 to 3.27) 0.91  -0.19 (-3.61 to 3.53) 0.92 
HDL-cholesterol x Time  0.59 (-1.14 to 2.32) 0.51  -0.01 (-3.62 to 3.61) 0.99  -0.04 (-3.85 to 3.69) 0.97 
Triglycerides (log) x Time   -0.01 (-1.03 to 1.00) 0.98   0.19 (-2.03 to 2.40) 0.87  0.39 (-1.88 to 2.66) 0.73 
Model 1: Adjusted for baseline covariates (age, sex, cholesterol, triglycerides), and their interactions with time. 
Model 2: Model 1 + baseline (height, education level, homocysteine) and time-dependent (BMI, hypertension, diabetes mellitus, coronary artery disease, 
psychotropic drugs, aspirin) covariates, and their interactions with time. 
Model 3: Model 2 and time-dependent covariates (MMSE, alcohol, smoking, NSAIDs, physical activity, depressive symptoms), and their interactions with time. 
 
 
